The FDA is facing scrutiny regarding mifepristone safety after study findings prompted the Trump administration to launch an investigation into drug safety.
12 reports, 2 independent
Updated Jul 28
Gone quiet
- Reports
- 12
- Developments
- 1
- Repetition
- 92%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is facing scrutiny regarding mifepristone safety after study findings prompted the Trump administration to launch an investigation into drug safety.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
- The FDA is facing public scrutiny due to oversight failures, leading to the introduction of new legislation targeting agency shortcomings.
- FDA is reviewing a new sunscreen ingredient while NPR reports on Donald Trump's political tensions.
- IGC Pharma, Inc. is preparing data for potential U.S. FDA review and seeking EMA support for its lead drug candidate.
- FDA issued a nationwide recall of pasta sold at Walmart following an investigation triggered by state department sampling.
- Trump administration slashes food safety enforcement and reduces workforce at FDA, FSIS, and CDC.
Coverage
Newest first; wire copies grouped- wkzo.comUS judge says Biden-era restrictions on prescribing abortion drug are unlawful
- dailysignal.com